Results: 12

Concomitant use of allopathic medicine and herbal products for weight-loss among people with overweight or obesity from Central Mexico

This study evaluated the prevalence of concomitant use of herbal products for weight loss (HPWL) and allopathic medicine. Factors associated with the prevalence, adverse reactions, and the alteration of medication adherence with the concomitant use of HPWL alone and i...

Alternativas fitoterápicas no controle da obesidade

Nos últimos anos, a obesidade vem aumentando consideravelmente entre adultos e crianças e, segundo a OMS, estima-se que em 2025 o número de obesos ultrapasse a 2,3 milhões em todo o mundo. O indivíduo obeso apresenta maiores riscos de desenvolver doenças crônicas não transmissíveis, como diabete...

Lisdexamfetamine to improve excessive daytime sleepiness and weight management in narcolepsy: a case series

Objective: To report the successful use of lisdexamfetamine in the management of narcolepsy. Methods: Five narcoleptic patients received lisdexamfetamine, at different dosages and for different periods, for management of excessive daytime sleepiness and weight control. Results: All patients experienced...

Non-caloric sweeteners and body weight

Medicina (B.Aires); 79 (2), 2019
Both total caloric intake and consumption of free sugars is higher than recommended. This situation contributes, among many other factors, to the increase of overweight and obesity in the population. To maintain the sweet taste of foods and beverages while reducing the caloric content and the amount of f...

Oral insulin improves metabolic parameters in high fat diet fed rats

An. acad. bras. ciênc; 89 (3), 2017
ABSTRACT Introduction/Aim: The gut has shown to have a pivotal role on the pathophysiology of metabolic disease. Food stimulation of distal intestinal segments promotes enterohormones secretion influencing insulin metabolism. In diabetic rats, oral insulin has potential to change intestinal epithelium be...

Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients

Clinics; 72 (5), 2017
The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. M...

Gender differences in biochemical markers and oxidative stress of rats after 28 days oral exposure to a mixture used for weight loss containing p-synephrine, ephedrine, salicin, and caffeine

Braz. j. pharm. sci; 52 (1), 2016
ABSTRACT The association of p-synephrine, ephedrine, salicin, and caffeine in dietary supplements and weight loss products is very common worldwide, even though ephedrine has been prohibited in many countries. The aim of this study was to evaluate a 28-day oral exposure toxicity profile of p-synephrine, ...

Intervenções nutricionais na promoção da perda de peso: faseolamina - revisão sistemática com metanálise e alimentos com possíveis benefícios - revisão sistemática para construção de tecnologia educacional

A obesidade é uma doença crônica não transmissível e considerada epidemia mundial com prevalência alarmante. Está associada à morbimortalidade e é fator de risco para doença cardiovascular (DCV), diabetes mellitus tipo 2 (DM2), hipertensão arterial sistêmica(HAS), dislipidemias, osteoartrite ...

Eficácia e tolerabilidade das substâncias calorigênicas: ioimbina, triiodotironina, aminofilina combinada a efedrina e feniolpropanolamina no tratamento da obesidade a curto prazo
Efficacy and tolerability of calorigenic substances: yoimbine, triiodothyronine, aminophylline combined with ephedrine and phenylpropanolamine in the short term obesity treatment

Objetivo: Determinar a eficácia e tolerabilidade de 4 substâncias calorigênicas: ioimbina, triiodotironina (T3), combinação efedrina-aminofilina e fenilpropanolamina (FPA). Material, Métodos e Desenho da Pesquisa: 103 mulheres obesas (30 < BMI < 40kg/m 2 ), de 18 a 55 anos, foram submetidas a estud...

Experiência clínica com o uso conjunto de sibutramina e orlistat em pacientes obesos
Clinical experience with the suite use of sibutramine and orlistat in obese patients

Avaliamos a eficácia e a tolerabilidade da associação de sibutramina (10mg) e orlistat (120mg três vezes por dia às refeições) no tratamento da obesidade em um estudo aberto de três meses de duração. O estudo envolveu 114 pacientes não diabéticos com sobrepeso ou obesidade em busca de tratame...